Medical device developer DFine announced the first patient has been enrolled in the EU-Star Clinical Trial.
The trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with the company's Star percutaneous targeted radiofrequency ablation therapy system for the palliative treatment of metastatic spinal tumors. DFine will enroll 40 patients at five centers in Germany and France.
The trial will evaluate pain relief at one month as a primary outcome measure with follow-up through six months. The trial's first patient was treated at the Otto-von-Guericke University Magdeburg in Germany, according to the vendor.
